Technical Analysis for NEXI - NexImmune, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Historical NEXI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 13.45% | |
| Hot IPO Pullback | Bullish Swing Setup | 13.45% | |
| Hot IPO Pullback | Bullish Swing Setup | 4.80% | |
| Outside Day | Range Expansion | 4.80% | |
| New 52 Week Closing Low | Bearish | 8.72% | |
| Inside Day | Range Contraction | 4.45% | |
| New 52 Week Closing Low | Bearish | 7.27% | |
| Inside Day | Range Contraction | 7.27% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakout | about 2 hours ago | |
| Hot IPO Pullback Entry | about 2 hours ago | |
| Rose Above Previous Day's High | about 2 hours ago | |
| Up 10% | about 2 hours ago | |
| Gap Up Closed | about 3 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Multiple Myeloma Leukemia Immune Mediated Diseases
Classification
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Multiple Myeloma Leukemia Immune Mediated Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.0 |
| 52 Week Low | 20.16 |
| Average Volume | 152,156 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 24.80 | ||||
| Resistance 3 (R3) | 25.10 | 24.47 | 24.34 | ||
| Resistance 2 (R2) | 24.47 | 23.77 | 24.33 | 24.19 | |
| Resistance 1 (R1) | 23.26 | 23.34 | 22.95 | 22.96 | 24.03 |
| Pivot Point | 22.63 | 22.63 | 22.48 | 22.49 | 22.63 |
| Support 1 (S1) | 21.42 | 21.93 | 21.11 | 21.12 | 20.05 |
| Support 2 (S2) | 20.79 | 21.50 | 20.65 | 19.89 | |
| Support 3 (S3) | 19.58 | 20.79 | 19.74 | ||
| Support 4 (S4) | 19.28 |
